☆ 4.8 Meeting Abstract

ACHIEVEMENT OF EARLY DEEP REMISSION IS ASSOCIATED WITH LOWER RATES OF WEEKLY DOSING FOR ADALIMUMAB-TREATED PATIENTS WITH CROHN'S DISEASE: DATA FROM EXTEND

GUT (2011)

Journal

GUT

Volume 60, Issue -, Pages -

Publisher

BMJ PUBLISHING GROUP

DOI: 10.1136/gut.2011.239301.290

Keywords

adalimumab; Crohn's disease; deep remission

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8

Not enough ratings

ACHIEVEMENT OF EARLY DEEP REMISSION IS ASSOCIATED WITH LOWER RATES OF WEEKLY DOSING FOR ADALIMUMAB-TREATED PATIENTS WITH CROHN'S DISEASE: DATA FROM EXTEND

Journal

GUT

Publisher

BMJ PUBLISHING GROUP

Keywords

Categories

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

ACHIEVEMENT OF EARLY DEEP REMISSION IS ASSOCIATED WITH LOWER RATES OF WEEKLY DOSING FOR ADALIMUMAB-TREATED PATIENTS WITH CROHN'S DISEASE: DATA FROM EXTEND

Journal

GUT

Publisher

BMJ PUBLISHING GROUP

Keywords

Categories

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Export Citation

Share Paper